Insurance Committee Meeting: Opioid Insurance Coverage Issues
Zoom (Registration Required)
Please join us for the next meeting of the Insurance Committee .
Open to the Public. Please register in advance for this meeting.
Opioid Insurance Coverage Issues
2020 was the deadliest year to date for opioid overdoses in North America, totaling more than 76,000. Simultaneously, opioid litigation is in full swing, and insurers are making difficult decisions about settlement, trials, and coverage. In 2021, prescription opioid manufactures prevailed in one of the first California trials. The Court found “there is simply no evidence to show that the rise in prescriptions was not the result of the medically appropriate provision of pain medications to patients in need.” In 2022, the opioid coverage litigation is expected to rachet up following the West Virginia Supreme Court of Appeals decision overturning of an injunction preventing insurers from pursing coverage litigation in California.
Against this backdrop, the insurance coverage asked to fund most settlements are now in focus. It is crucial to get ahead of the most pressing coverage issues driving the anticipated surge of coverage litigation. This panel will discuss the recent decisions and pending cases that are expected to provide further guidance on the most burning opioid coverage questions.
- Are municipal costs to combat the opioid epidemic “for” or “because of” bodily injury, which is the typical language either to trigger CGL coverage or to exclude coverage under non-CGL policies?
- Are the damages the result of intentional conduct; do they constitute an “occurrence”?
- Are newer insurance policies absolved under loss-in-progress provisions?
- Do opioid losses fall within product exclusions?
- How Self-Insured Retentions could affect the interplay of policies?